Understanding Cialis: The Lilly Brand Medication

"We expect that the entry of generic competition

• Cialis Lilly is part of a broader portfolio by Eli Lilly that addresses several medical conditions.
• Its patent expiration has led to more affordable generics entering the market.
• Lilly maintains stringent manufacturing standards for Cialis products.
• Patients should disclose all medications and health conditions before starting Cialis.
• The brand conducts patient assistance programs for affordability in some regions.
• Cialis Lilly tablets are scored for easy splitting if needed to adjust dose.
• Erectile dysfunction can also be influenced by psychological factors; Cialis addresses physical causes.
• Cialis Lilly must be taken cautiously in patients with heart conditions.
• Regular medical follow-up is recommended to monitor effectiveness and safety.
• Cialis Lilly promotes balanced lifestyle as part of overall ED management.

following the loss of exclusivity will cause a rapid

• Patient adherence to Cialis Lilly treatment plans correlates strongly with improved life quality.
• Prescription guidelines emphasize starting at low doses to assess tolerance.
• Cialis Lilly’s dual indication makes it unique among PDE5 inhibitors.
• Healthcare providers assess cardiovascular status before recommending Cialis.
• Individualized therapy may include combination with lifestyle changes and counseling.
• Medical advances continue to explore new applications of tadalafil beyond ED and BPH.
• Cialis Lilly tablets are easy to swallow and designed for convenient daily use.
• The brand supports clinical research through sponsorships and grants.
• Cialis Lilly has contributed to destigmatizing erectile dysfunction in public health.
• Patient testimonials often highlight restored intimacy and confidence following treatment.

and severe decline in revenue," the company stated in

Tadalafil or Cialis: Are They Basically The Same?

Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by the management of ICOS and Lilly. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological, legal and other factors discussed in the two companies' respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies and Lilly ICOS. Results and the timing and outcome of events may differ materially from those expressed or implied by the forward-looking statements in this press release. More specifically, there can be no assurance that Cialis will achieve commercial success or that competing products will not pre-empt market opportunities that might exist for the product. Cialis® is a registered trademark of Lilly ICOS LLC.

How to flush Cialis out of your system?

All other trademarks are the property of their respective owners. Viagra® is a registered trademark of Pfizer, Inc. The term "new treatment initiations" indicates when a physician writes out a new prescription for patients never before treated, and for patients switching from one product to another. This does not include prescriptions conveyed to pharmacies by phone or refills of existing prescriptions. In this release, new treatment initiations describes data from ImpactRx only.

Side Effects of Cialis:

ImpactRx™ has a panel of high prescribing physicians that recorded information on patient visits (patient identity is non-identifiable), including diagnosis and treatment. ImpactRx data includes new prescriptions written and refills but not great britain drugs generic cialis prescriptions conveyed by phone. ImpactRx records information from the physician perspective and not what happens at the pharmacy. Computed from IMS NPA Plus™, April 2004. IMS numbers vary from those of ImpactRx primarily because IMS data represent aggregated pharmacy sales, reflecting what is filled at the pharmacy including new prescriptions for continuing users and prescriptions called in by phone. its year-end filing with the Securities and Exchange Commission.

Such a steep decline will be a heavy blow for Lilly's

bottom line, even if it comes a year later than previously expected. Lilly has weathered major patent losses before.

• Cialis Lilly’s molecular formula is C22H19N3O4, corresponding to tadalafil’s chemical structure.
• The medication selectively inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels.
• This action relaxes smooth muscles and improves blood flow in the corpus cavernosum.
• Cialis Lilly is marketed in tablets colored yellow with distinctive markings for brand recognition.
• The product is available in strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg tablets.
• Patients are advised to keep Cialis Lilly out of the reach of children.
• Stability and shelf life are ensured by compliant packaging and storage conditions.
• The brand invests in research to investigate new therapeutic potentials of tadalafil.
• Generic versions must meet stringent bioequivalence standards set by regulators.
• Cialis Lilly is recognized for reliability and patient trust globally.

In 2013, sales of its antidepressent and pain drug Cymbalta (duloxetine) topped $5 billion —

What About Other ED Medications?

ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community. Eli Lilly doesn't expect to see generic competition to its second best-selling drug Cialis (tadalafil) until after September 2018, announcing Wednesday it had entered into a settlement agreement with generic drugmakers to resolve pending patent litigation over the erectile dysfunction treatment. Lilly had been battling generic companies in federal district court over a patent covering Cialis' unit dose, which was previously due to expire in April 2020. Under the settlement agreement, Cialis exclusivity will end at the earliest on September 27, 2018.

Brand Choices

That date is nearly a year after Lilly expects to lose patent protection on other compound and use patents which cover the drug through November 2017. In a statement, Lilly's general counsel Michael Harrington said the agreement provides Lilly with more certainty around its U.S. exclusivity. With the agreement, Lilly extends the runway for Cialis, staving off a more immediate blow to revenues. That generic threat still looms in the near-future, however, and will post a challenge to Lilly's financial growth.

Most Recent Events

The Indianapolis drugmaker has committed to hitting 5% annual revenue growth through 2020, betting a wave of new drugs will help see it through another rough patch of patent expiries. Copycat versions of Eli Lilly's ADHD drug Strattera (atomoxetine) launched earlier this year, and the company anticipates losing exclusivity for its blood-thinner Effient (prasugrel) in October. A recent legal victory in the U.K.'s top court, however, should help Lilly defend its cancer drug Alimta (pemetrexed), which also faces inbound rivals. Cialis is Lilly's second best-selling product and accounted for nearly 12% of total revenues last year with $2.47 billion in sales. In the U.S., recent growth has come from higher realized prices as the pharma anticipates the looming patent cliff. only to collapse down to $1.6 billion the next year after its patent protection expired.

• Cialis Lilly has been extensively studied, with thousands of patients in clinical trials worldwide.
• Data supports its safety profile when used according to recommendations.
• It has shown positive effects on patient satisfaction and relationship quality.
• Cialis Lilly is compatible with common antihypertensive medications, but care is advised.
• Patients should inform physicians about allergies to tadalafil or other substances.
• Pregnant or breastfeeding women should avoid Cialis Lilly entirely.
• Cialis Lilly should not be shared; it is personalized medication.
• Lifestyle factors such as smoking and obesity influence treatment success.
• Cialis Lilly packaging includes detailed patient leaflets for education.
• It remains a key product in Eli Lilly’s sexual health treatment line.

This time, though, Lilly hopes a group of newly approved and launched drugs —

headlined by Trulicity (dulaglutide) and Taltz (ixekizumab)

Summary of Market and Financial Outlook

The most common side effects with Cialis were headache, upset stomach, delayed backache and muscle ache. Although rare, men who experience an erection for more than four hours should seek immediate medical attention. Men should not drink alcohol in excess with Cialis. Cialis studies were not designed to assess multiple intercourse attempts after a single dose. ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse.

Market Size and Growth Rate

ED affects an estimated 152 million men and their partners worldwide.10 Experts believe that 80 - 90 percent of ED cases are related to a physical or medical condition, like diabetes, cardiovascular diseases, and prostate cancer treatment, while 10 - 20 percent are due to psychological causes.11,12 In many cases, however, both psychological and physiological factors contribute to the condition.13 Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, developed tadalafil for the treatment of erectile dysfunction. Lilly, a leading innovation-driven corporation is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at ICOS Corporation, a biotechnology company, is dedicated to bringing innovative therapeutics to patients. Headquartered in Bothell, Wash., ICOS is marketing its first product, Cialis (tadalafil), for the treatment of erectile dysfunction.

What is Cialis?

ICOS is working to develop treatments for serious unmet medical conditions such as chronic obstructive pulmonary disease, cancer and inflammatory diseases. B-roll is available via satellite, C-band feed: WEDNESDAY, JUNE 2, 10:30 - 11:00 AM EDT C-Band, IA 6, Tr. WEDNESDAY, JUNE 2, 13:15 - 13:45 PM EDT C-Band, IA 5, Tr. THURSDAY, JUNE 3, 13:00 - 13:30 PM EDT C-Band, IA 5, Tr. Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. — can keep revenue growth on track.

What Are the Current Market Dynamics for Tadalafil?

"The Three PDE 5 Inhibitors Sildenafil, Tadalafil And Vardenafil - Results Of A Comparative Preference Trial In 222 Patients With Erectile Dysfunction," Hartmut Porst, et. al., presented in poster session at American Urological Association Annual Meeting, May 2004. Computed from IMS NPA PlusTM, April 2004. The Likely Worldwide Increase in Erectile Dysfunction Between 1995 and 2025 and Some Possible Policy Consequences. Back To Great Sex: Overcome ED and Reclaim Lost Intimacy.

Manufacturers’ Strategies

Singapore, 5 February 2024 Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of two brands, Cialis® (Tadalafil) and Alimta® (Pemetrexed), from Eli Lilly and Company (“Lilly”) for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte. Zanovex will own the trademarks and marketing authorisations, and license manufacturing know-how for Alimta®, an established chemotherapy drug for the treatment of a certain type of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis®, a leading men’s health product for the treatment of erectile dysfunction. ZP Therapeutics, the commercial division of Zuellig Pharma, will promote the two brands in the relevant markets. Prior to the acquisition, ZP Therapeutics was responsible for the promotion and distribution of the brands as part of a broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand. “This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company.

Safety and Storage:

We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia,” said John Graham, Group CEO, Zuellig Pharma. Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical canadian pharmacy no prescription cialis companies in the world.